PFE Pfizer Inc
Company Analysis
Latest News
Pfizer’s Litfulo Hits Phase 3 Goals for Vitiligo, Eyes Global Filings
Pfizer reported positive topline results from two Phase 3 trials evaluating Litfulo for nonsegmental vitiligo. The TRANQUILLO and TRANQUILLO 2 studies met...
Sanofi Sues Pfizer and Moderna, Alleging Blockbuster COVID-19 Vaccine Patent Infringement
Sanofi filed lawsuits against Pfizer and Moderna in a New Jersey federal court. The French pharmaceutical company alleges their COVID-19 vaccines infringe upon...
Pfizer freezes Polish air-traffic funds, seeking €1.3B for unpaid vaccines
Pfizer is enforcing a Belgian court ruling ordering Poland to pay €1.3 billion for COVID-19 vaccines. The legal action follows the Polish government's refusal...
Pfizer Rises, AstraZeneca Heart Drug Failure Protects Vyndamax Market
Pfizer shares rose approximately 1% in pre-market trading. The move followed an announcement from AstraZeneca and Ionis Pharmaceuticals regarding the...
Pfizer Downgraded to Hold, Hit by Lung Cancer Drug Trial Setback
HSBC downgraded Pfizer (PFE) from Buy to Hold. The bank lowered its 12-month price target for the stock from $32.00 to $28.00. A Phase 3 trial setback for...
Pfizer GLP-1 drug clears China insurance hurdle, targeting wider patient access
Pfizer’s GLP-1 candidate ecnoglutide passed the National Healthcare Security Administration's preliminary review for China’s national medical insurance...
🟢 PFE is trading 2.5% up today after FDA expands IBRANCE breast cancer indication
PFE is trading 2.5% up at $24.27 after the FDA approved an expanded indication for its breast cancer drug, IBRANCE. • The June 24, 2026, decision allows...
Pfizer Wins FDA Approval for IBRANCE, Cutting Breast Cancer Progression Risk 24%
Pfizer received U.S. Food and Drug Administration (FDA) approval for the expanded use of IBRANCE (palbociclib). The approval covers maintenance treatment for...
🔴 PFE is trading 2% down today after mixed Phase 3 lung cancer trial results
PFE is trading 2% down today at $24.23, extending its recent multi-day slide. Investors are reacting to: • Mixed topline Phase 3 results for Pfizer's...
Pfizer pauses major acquisitions for AI efficiency, targeting stock recovery
Pfizer is pausing large-scale acquisitions to prioritize operational transformation through artificial intelligence. This shift follows the $43 billion...
Pfizer Reaffirms Full-Year 2026 Financial Guidance Amid CFO Transition
Pfizer has reaffirmed its full-year 2026 financial guidance, which was originally introduced on December 16, 2025. The company confirmed its outlook following...
🔴 Pfizer Inc is trading 2.8% down today after CFO departure news
Pfizer Inc is trading at $25.20 (-2.76%) following the announcement that Chief Financial Officer Dave Denton will step down on August 15, 2026. • The company...
Pfizer CFO Dave Denton to Depart; Cecile Guegan Appointed Interim CFO
Pfizer announced that Chief Financial Officer Dave Denton will step down from his role, effective August 15, 2026, to pursue an opportunity outside the...
Pfizer Advances Monthly Obesity Shot, Reporting 15.9% Weight Loss in Trial
Pfizer reported positive Phase 2b study results for berobenatide, an investigational once-monthly weight loss injection. Data presented at the American...
Pfizer’s Braftovi Slashes Cancer Progression Risk by 56% in Phase 3 Trial
Pfizer announced Phase 3 BREAKWATER trial results for BRAFTOVI (encorafenib) at the 2026 ASCO Annual Meeting. The study evaluated the drug combination in...
Pfizer Advances in Obesity Race with New Late-Stage Trial for Monthly Drug
Pfizer launched the VESPER-6 Phase 3 clinical trial for its weight-loss drug candidate, berobenatide. The study evaluates the safety and efficacy of a...
Pfizer cuts prostate cancer progression risk 52%, targeting specific gene mutations
Pfizer reported Phase 3 TALAPRO-3 study results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated a combination of...
Pfizer and Innovent partner on 12 cancer drugs in major global deal
Pfizer and Innovent Biologics have formed a global strategic collaboration to develop 12 early-stage cancer medicines. The partnership focuses on antibody-drug...
Pfizer and Partners Receive Positive EU CHMP Opinion for PADCEV Combination
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approving PADCEV in combination with Merck's Keytruda. The regimen...
Pfizer Advances 25-Valent Pediatric Pneumococcal Vaccine to Phase 3 After Strong Phase 2 Data
Pfizer announced that its investigational 25-valent pneumococcal conjugate vaccine (25vPnC) showed up to 15-fold higher antibody responses compared to Prevnar...